Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
p11 Protein Levels in Patients With Major Depressive Disorder Treated With Citalopram
This study is currently recruiting participants.
Verified by National Institutes of Health Clinical Center (CC), May 2008
Sponsored by: National Institute of Mental Health (NIMH)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00697268
  Purpose

This study will compare levels of p11 protein in people with and without major depressive disorder (MDD) and examine if p11 levels in patients are affected by treatment with citalopram (Celexa).

Healthy normal volunteers and patients with chronic or recurrent major depression between 18 and 65 years of age may be eligible for this study.

Participants undergo the following tests and procedures:

Healthy Volunteers

  • Psychiatric interview and medical examination, questions about family history
  • Blood draw

Patients with MDD

Phase 1 - Evaluation and Discontinuation of Medications

  • Physical examination, electrocardiogram, blood tests
  • Gradual antidepressant medication withdrawal, followed by 2- to 6-week drug-free period. If needed, medicines for anxiety and difficulty sleeping may be prescribed.

Phase 2 - Citalopram Treatment

  • Start daily citalopram treatment
  • Evaluations at the start of phase 2 and every week for 8 weeks with following procedures:
  • Symptoms ratings interview and questionnaires
  • Review of side effects and new medications
  • Blood pressure and pulse measurements
  • Blood and urine tests

At the end of the study, plans are developed for long-term treatment and transfer of care to the patient's own physician.


Condition
Depression

MedlinePlus related topics: Depression
Drug Information available for: Escitalopram Benzetimide Citalopram Citalopram hydrobromide Dexetimide Escitalopram oxalate Serotonin
U.S. FDA Resources
Study Type: Observational
Study Design: Prospective
Official Title: An Investigation to Determine Whether Levels of P11 Protein in Peripheral Blood Cells Correlate With Treatment Response to Citalopram in Patients With Major Depressive Disorder

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 82
Study Start Date: June 2008
Detailed Description:

Major depressive disorder (MDD) is a serious, debilitating, life-shortening illness that affects many persons of all ages and backgrounds. While treatments are effective for a significant portion of patients with MDD, progress in developing more effective treatments is lagging. Furthermore, with regards to existing antidepressant medications, there are yet no reliable predictors of the likelihood of remission, response or non-response with an initial trial of an antidepressant medication. Identifying factors that are likely to predict response would have the advantage of personalizing treatment to a particular individual; that is selecting the antidepressant medication that is most likely to give the greatest probability of having a favorable outcome.

The serotonin system has been implicated in the pathophysiology of depression and mechanism of action of existing effective antidepressant treatments. Fourteen different serotonin receptors have been identified to date. One of them, 5-HT1B, plays an important role in regulating serotonin neurotransmission. Recently, p11 (a member of the S100 family of proteins) was found to interact with 5-HT1B receptors (Svenningsson et al 2006; Svenningsson and Greengard 2007). p11 mRNA levels are markedly reduced in the forebrain in helpless H/Rouen mice and the level of p11 mRNA was down-regulated in the anterior cingulate cortex from depressed patients. p11 mRNA is distributed in an anatomical pattern that closely resembled that of 5-HT1B receptor mRNA, including cortex, hippocampus, hypothalamus and raphe nuclei. Chronic administration of the antidepressants imipramine, tranylcypromine, and citalopram significantly increase the level of p11 in cortex. Finally, we have found that chronic treatment with fluoxetine increases p11 in peripheral mononuclear cells in monkeys.

We will now study whether the blood cell levels of p11 differ between healthy individuals and patients suffering from unipolar depression. Moreover, we will study whether the levels of p11 are affected by treatment with the selective serotonin reuptake inhibitor, citalopram. Complementary work will continue at other laboratories to better characterize the role of p11 in the pathophysiology of depression (e.g., animal studies, post-mortem studies).

This is an open label study which will be performed at the National Institute of Mental Health. In all, 82 adult subjects with major depressive disorder, between the ages of 18 and 65 years, will be recruited from the community. In addition, we will perform p11 measurements in blood cells from 64 healthy control subjects.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA:

CRITERIA FOR INCLUSION OF DEPRESSED PATIENTS:

  • age 18-65 years
  • written informed consent completed (consent-incapacitated subjects will not be eligible)
  • score 20 or higher on the Montgomery-Asberg Depression Rating Scale (MADRS)
  • meets DSM-IV criteria for chronic or recurrent nonpsychotic MDD
  • patients who are on non-excluded concomitant medications.
  • no more than 3 failed antidepressant treatments within the current major depressive episode
  • no alcohol use (last 7 days)

CRITERIA FOR INCLUSION OF HEALTHY CONTROL SUBJECTS:

  • age 18-65 years
  • written informed consent completed
  • no current or past diagnosis of axis I psychiatric disorder (DSM-IVTR)
  • no alcohol use (last 7 days)
  • physically healthy

EXCLUSION CRITERIA:

CRITERIA FOR EXCLUSION OF DEPRESSED PATIENTS:

  • history of bipolar disorder (I, II, or NOS) (lifetime)
  • history of schizophrenia
  • history of schizoaffective disorder or
  • psychosis NOS (lifetime)
  • history of anorexia nervosa or bulimia nervosa (lifetime)
  • current primary obsessive-compulsive disorder (OCD)
  • history of clear-cut intolerability to the study medication
  • lack of response to an adequate trial of the study medication (citalopram) in the current or past episodes of MDD
  • did not respond to 7 or more sessions of ECT in the current episode of MDD
  • Serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease.
  • has general medical condition which contraindicates the use of the study medication
  • is on concomitant medication which contraindicates the use of the study medication
  • requires immediate hospitalization for psychiatric disorder
  • requires antipsychotic medications or mood stabilizers
  • Non-postmenopausal (less than 2 years since last period) females of childbearing potential who are sexually active and who are not using adequate (hormonal, double barrier, surgical) contraception, or who are pregnant or breast feeding
  • patients currently taking any of the exclusionary medications detailed in protocol (including antipsychotic medications, anticonvulsant medications, antidepressant medications, mood stabilizers, central nervous system stimulants) in the 2 weeks prior to Study Period II.
  • patients taking thyroid medication for hypothyroidism may be included if they have been stable on the medication for greater than 3 months
  • patients can participate in a modality of psychotherapy that is not targeting the symptoms of depression (e.g., supportive therapy, marital therapy)
  • therapy that is depression specific, such as Cognitive Therapy (CT) or Interpersonal Psychotherapy of Depression (IPT) is not allowed during participation
  • subjects must be fluent in English and have the capacity to understand the nature of the study and sign the written informed consent.
  • current alcohol dependence or abuse (last 3 months)

CRITERIA FOR EXCLUSION OF HEALTHY CONTROL SUBJECTS:

  • subjects currently taking any of the exclusionary medications detailed in protocol in the 2 weeks prior to evaluation
  • current alcohol dependence or abuse (last 3 months)
  • history of major depression or bipolar disorder in any first degree relative
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00697268

Contacts
Contact: Patient Recruitment and Public Liaison Office (800) 411-1222 prpl@mail.cc.nih.gov
Contact: TTY 1-866-411-1010

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
  More Information

NIH Clinical Center Detailed Web Page  This link exits the ClinicalTrials.gov site

Publications:
Study ID Numbers: 080150, 08-M-0150
Study First Received: June 12, 2008
Last Updated: August 8, 2008
ClinicalTrials.gov Identifier: NCT00697268  
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Depression
Depression Treatment
Unipolar Depression
Citalopram
Serotonin
Major Depression
Healthy Volunteer
HV

Study placed in the following topic categories:
Depression
Mental Disorders
Mood Disorders
Healthy
Depressive Disorder, Major
Dexetimide
Depressive Disorder
Citalopram
Serotonin
Behavioral Symptoms

Additional relevant MeSH terms:
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Serotonin Agents
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Physiological Effects of Drugs
Psychotropic Drugs
Antidepressive Agents, Second-Generation
Serotonin Uptake Inhibitors
Central Nervous System Agents
Pharmacologic Actions
Antidepressive Agents

ClinicalTrials.gov processed this record on January 30, 2009